Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 9:20 AM Eastern Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://wsw.com/webcast/leerink26/fprx. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
